V. Giannone

Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

H. Groen, Bruce E. Johnson, E. Smit, 2016, The Lancet. Oncology.

Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open‐label, phase I study

J. Schopohl, J. Bollerslev, A. Arafat, 2014, Journal of clinical pharmacology.

Safety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I study

E. Wolin, V. Giannone, K. Hu, 2013, Cancer Chemotherapy and Pharmacology.

Long-term safety and efficacy of deferasirox (Exjade®) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease

E. Vichinsky, A. Kutlar, T. Coates, 2011, British journal of haematology.

Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study.

H. Groen, M. Socinski, E. Smit, 2017 .

Improvement in liver pathology of patients with β-thalassemia treated with deferasirox for at least 3 years.

P. Brissot, M. Cappellini, Y. Deugnier, 2011, Gastroenterology.

Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.

A. Shaw, E. Felip, F. D. De Braud, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)

H. Groen, D. Planchard, J. Mazières, 2017 .